Published in Surg Clin North Am on October 01, 1994
Lymphatic disorders after renal transplantation: new insights for an old complication. Clin Kidney J (2015) 0.79
Donor kidney recovery methods and the incidence of lymphatic complications in kidney transplant recipients. Int J Organ Transplant Med (2010) 0.75
Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs). Clin Kidney J (2014) 0.75
Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro (1976) 2.65
The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54
Salt extraction of soluble HL-A antigens. Science (1971) 2.18
Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation (1985) 1.83
Transplantation antigens. Adv Immunol (1970) 1.70
En bloc transplantation of kidneys from pediatric donors. J Urol (1996) 1.51
The synergistic effects of cyclosporine and sirolimus. Transplantation (1997) 1.47
Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc (1988) 1.44
Ranitidine, cimetidine, and the cyclosporine-treated recipient. Transplantation (1986) 1.44
Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol (1997) 1.43
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation (1999) 1.42
HLA matching assessed from early graft function. Transplant Proc (1987) 1.40
Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation (1998) 1.36
Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet (2001) 1.36
Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone. Transplantation (1983) 1.35
Immunopharmacological monitoring of cyclosporin A-treated recipients of cadaveric kidney allografts. Transplantation (1982) 1.28
Binding of cyclosporine by human lymphocytes and phospholipid vesicles. J Immunol (1983) 1.26
The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med (1994) 1.26
De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery (1985) 1.24
Partial artificial heart (ALVAD) use with subsequent cardiac and renal allografting in a patient with stone heart syndrome. Artif Organs (1978) 1.23
Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant (2009) 1.22
Biological and chemical characterization of human histocompatibility antigens. Fed Proc (1971) 1.19
Transplantaton antigens. Science (1969) 1.18
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation (2000) 1.18
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol (2001) 1.17
Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol (2000) 1.14
Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation (1987) 1.13
Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation (1991) 1.12
Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch? Transplantation (1998) 1.09
New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem (2000) 1.07
The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int (1996) 1.06
Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation (1991) 1.05
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther (1993) 1.05
Clinicopathological correlations of disseminated intravascular coagulation in patients with head injury. Neurosurgery (1984) 1.04
Human colon adenocarcinoma cells. II. Tumorigenic and organoid expression in vivo and in vitro. J Natl Cancer Inst (1977) 1.03
Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem (1996) 1.02
Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy (1998) 1.01
Cyclosporine: the agent and its actions. Transplant Proc (1985) 1.01
Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation (1999) 1.00
Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation (2001) 0.98
Specific tumor immunity induced with soluble materials: restricted range of antigen dose and of challenge tumor load for immunoprotection. J Immunol (1975) 0.98
Distribution of sirolimus in rat tissue. Clin Biochem (1997) 0.97
Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc (2011) 0.96
Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc (2003) 0.96
Serologic methods for the early diagnosis of Pneumocystis carinii infection in renal allograft recipients. Transplantation (1986) 0.95
Use of cyclosporine in pediatric renal transplant recipients. J Pediatr (1985) 0.95
Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients. Transplantation (1980) 0.95
Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation (1987) 0.94
Cyclosporin A: a selective anti-T cell agent. Clin Haematol (1982) 0.94
Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis (1999) 0.94
Soluble tumor-specific transplantation antigens from methylcholanthrene-induced guinea pig sarcomas. Cancer (1970) 0.94
Electrophoretic purification of a water-soluble guinea pig transplantation antigen. Proc Natl Acad Sci U S A (1967) 0.93
Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients. Transplantation (1990) 0.93
Complications in cardiac transplant patients requiring general surgery. Surgery (1988) 0.92
Preemptive transplantation--an analysis of benefits and hazards in 85 cases. Transplantation (1991) 0.92
Impact of cyclosporine on renal transplant practice at the University of Texas Medical School at Houston. Am J Kidney Dis (1985) 0.92
Advances in the chemistry of transplantation antigens. Transplant Proc (1969) 0.91
Nutrition and host defense mechanisms. Surg Clin North Am (1981) 0.91
Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation (1991) 0.90
Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther (1992) 0.90
New-onset diabetes after renal transplantation: diagnosis, incidence, risk factors, impact on outcomes, and novel implications. Transplant Proc (2011) 0.90
Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplant Proc (2009) 0.90
Extraction and purification of soluble histocompatibility antigens. Transplant Rev (1971) 0.89
Chemical markers of transplantation individuality solubilized with sonic energy. Bacteriol Rev (1971) 0.89
Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical, but negative preoperative, donor crossmatches. Transplantation (1985) 0.89
100 living-related kidney donor evaluations using digital subtraction angiography. Transplantation (1985) 0.89
Differences in the amino acid compositions of allogeneic guinea pig transplantation antigens. J Immunol (1968) 0.89
The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis (1985) 0.89
Extraction of a murine tumor-specific transplantation antigen with 1-butanol. I. Partial purification by isoelectric focusing. J Natl Cancer Inst (1980) 0.89
Enhancement of heterotopic cardiac allograft survival by experimental biliary ligation. Transplantation (1987) 0.88
The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc (1984) 0.88
Causes of graft loss beyond two years in the cyclosporine era. Transplantation (1990) 0.88
The use of cyclosporine in living-related renal transplantation. Donor-specific hyporesponsiveness and steroid withdrawal. Transplantation (1984) 0.88
Effect of FK 506 and cyclosporine on heart allograft survival in rats. Transplant Proc (1991) 0.87
Gestational trophoblastic disease: origin of choriocarcinoma, invasive mole and choriocarcinoma associated with hydatidiform mole, and some immunologic aspects. Adv Cancer Res (1978) 0.87
Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation (1989) 0.87
Nucleotide sequences of three H-2K and three H-2D complementary DNA clones coding mouse class I MHC heavy chain proteins. Ann Transplant (1996) 0.87
Cyclosporin A tissue levels in a cadaveric renal allograft recipient. Transplantation (1983) 0.87
Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene. Transplant Proc (2005) 0.87
The effect of purification on the immunogenicity of tumor-specific transplantation antigens. Cancer Immunol Immunother (1985) 0.86
Effect of murine tumors upon delayed hypersensitivity to dinitrochlorobenzene. III. In vivo activity of the nonspecific suppressor cell. J Immunol (1981) 0.86
Effects of cyclosporine, azathioprine and prednisone on Kimura's disease and focal segmental glomerulosclerosis in renal transplant patients. Clin Nephrol (1996) 0.86
HL-A antigens from a continuous lymphoid cell line derived from a normal donor. I. Solubilization and serologic characterization. J Immunol (1970) 0.85
Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat. Transplantation (1988) 0.85
Cosmas and Damian in the 20th century. N Engl J Med (1981) 0.85
Clinical and experimental studies with cyclosporine in renal transplantation. Surgery (1985) 0.85
The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Transplantation (1999) 0.85
The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc (1984) 0.85
Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Transplantation (1987) 0.85
AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation (1991) 0.85
Sirolimus improves the two-year outcome of renal allografts in African-American patients. Transpl Int (2001) 0.85
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther (2001) 0.85
Human colon adenocarcinoma cells. III. In vitro organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture. J Natl Cancer Inst (1979) 0.84
FTY 720 prevents ischemic reperfusion damage in rat kidneys. Transplant Proc (2001) 0.84
Kidney donation: needs and possibilities. Neurosurgery (1979) 0.84
Five years' experience with cyclosporine in children. Transplant Proc (1988) 0.84
Case report--sirolimus rescue therapy for refractory renal allograft rejection. Transplantation (1996) 0.84
Demonstration by radionuclide imaging of possible vascular steal from a renal transplant. J Nucl Med (1979) 0.84
Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol (2001) 0.84